Zydus Lifescience Share Price Falls in 2025: Real Reasons Behind the Drop Revealed

Introduction: Zydus Lifescience Share Price Fall

Zydus Lifescience is one of the major companies in our country that exports its medicines from India in the pharmaceutical sector. However, by the end of July, this stock has dropped by around 22% to 23% over the past one year, and now this share has created a tense atmosphere in the market among investors due to the Zydus Lifescience Price share fall, especially when compared to Sensex and NSE, which have only fallen by around 0.68% to 1%.

The current fall we are witnessing in Zydus Lifescience share does not seem to be just a small short-term rally. There might be some geopolitical reasons behind this, which we will explore in depth in the upcoming part of the article.

Zydus Lifesciences Stock Current Situation:

Zydus’ share has been facing a lot of instability since July-August. For example, around the 8th, the share fell by 1.6%, and after a while, around 31st July, it fell again by 3%, which added to the stock’s one-year-long decline.

And if we look at the stock chart from the last few days, then in the past 10 to 20 days, it has been trading downward, while if we look long-term from around 50 to 200 days, it has been trading upward, which gives confidence to long-term investors. And even after the Zydus Lifescience share Price fell, some investors believe that this share is still strong for the long term.

Main Reasons Behind the Fall:

The main reason behind the Zydus Lifescience share Price fall is something most people are unaware of — they don’t know why the share is falling while other competitor companies haven’t fallen this much.

The main reason behind Zydus’ decline is that the company was selling a drug named Mirabegron in the US, which was used for the treatment of an overactive bladder. When Zydus lost the patent case in the US, Zydus suffered a major setback. A company named Astellas Pharma filed a patent violation case and won.

The second major reason is the warning letter from the USFDA, which was sent to the company in August 2024. Then in June 2025, some other issues were also highlighted, which have now become a challenge for the company. Now investors are also hesitant. All these factors together have delivered a big blow to Zydus.

Conclusion:

The Zydus Lifescience share Price fall may not be a good sign for the company in the short term, but for long-term investors, this could be a buying opportunity — provided the company resolves all its legal issues quickly, then nothing can stop the share from moving upward.

Even though the company’s shares have fallen for some time, the company’s fundamentals are very strong, and the future growth of the pharma sector in India is very bright. And many big investors believe that the future growth of Zydus is quite good — especially if it doesn’t rely only on the US and starts exporting its products to other countries as well.

Disclaimer

All the information on this website 360Storyline.com is for educational and informational purposes only. We share updates on the stock market, crypto, finance, commodities, and success stories–but this is not investment advice. Please talk to a financial advisor before making any investment decisions. Markets have risks–there can be profit or loss. By using this website, you fully accept and agree to this Disclaimer.

Hello everybody! If you’ve read this article, you’re probably interested in investing in stocks for 2025. But we request you to do your own research before buying any stock or investing under the guidance of an expert. For more such knowledgeable articles, follow 360Storyline -Financial Process Buddy.